These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 21862455

  • 1. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.
    Slagman MC, Waanders F, Vogt L, Damman K, Hemmelder M, Navis G, Laverman GD.
    Nephrol Dial Transplant; 2012 Mar; 27(3):983-90. PubMed ID: 21862455
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH, NIGRAM Consortium.
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [Abstract] [Full Text] [Related]

  • 4. Vascular endothelial growth factor C levels are modulated by dietary salt intake in proteinuric chronic kidney disease patients and in healthy subjects.
    Slagman MC, Kwakernaak AJ, Yazdani S, Laverman GD, van den Born J, Titze J, Navis G.
    Nephrol Dial Transplant; 2012 Mar; 27(3):978-82. PubMed ID: 21778278
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 7. Benefits of dietary sodium restriction in the management of chronic kidney disease.
    Krikken JA, Laverman GD, Navis G.
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):531-8. PubMed ID: 19713840
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
    Kwakernaak AJ, Waanders F, Slagman MC, Dokter MM, Laverman GD, de Boer RA, Navis G.
    J Hypertens; 2013 Dec; 31(12):2425-32. PubMed ID: 24029871
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial.
    Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, Marcotte F, Mercier LA.
    Circulation; 2005 Oct 18; 112(16):2411-6. PubMed ID: 16216961
    [Abstract] [Full Text] [Related]

  • 12. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep 18; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 13. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.
    Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G.
    J Am Soc Nephrol; 2008 May 18; 19(5):999-1007. PubMed ID: 18272844
    [Abstract] [Full Text] [Related]

  • 14. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 18; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 15. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
    Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B.
    Acta Biochim Pol; 2010 Jan 18; 57(1):119-23. PubMed ID: 20309434
    [Abstract] [Full Text] [Related]

  • 16. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.
    Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, Groen H, Laverman GD, Navis G, Holland Nephrology Study (HONEST) Group.
    Lancet Diabetes Endocrinol; 2014 May 18; 2(5):385-95. PubMed ID: 24795252
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.
    Am Heart J; 2008 May 23; 155(5):791-805. PubMed ID: 18440325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.